SEC Comment Letter for Trillium Therapeutics Inc. (CIK 0001616212) — May 6, 2020
Trillium Therapeutics Inc. (CIK 0001616212)
Date: May 6, 2020 · CIK: 0001616212 · Accession: 0000000000-20-003968
AI Filing Summary & Sentiment
File numbers found in text: 333-237810
Letter
United States securities and exchange commission logo April 30, 2020 James Parsons Chief Financial Officer Trillium Therapeutics Inc. 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada Re:Trillium Therapeutics Inc. Registration Statement on Form F-3 Filed April 23, 2020 File No. 333-237810 Dear Mr. Parsons: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Haran Viswanathan
Show Raw Text
United States securities and exchange commission logo
April 30, 2020
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
2488 Dunwin Drive
Mississauga, Ontario L5L 1J9
Canada
Re:Trillium Therapeutics Inc.
Registration Statement on Form F-3
Filed April 23, 2020
File No. 333-237810
Dear Mr. Parsons:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Haran Viswanathan